Mille, is this what you are talking about?
http://content.onlinejacc.org/cgi/content/full/49/1/122
"In recent studies, an association between early noncardiac surgery after PCI and adverse cardiac outcome has been reported as well (
1,2,5). However, these reports did not include the use of drug-eluting stents. The excessive risk of early surgery after PCI might be attributable to the high risk of in-stent thrombosis during the perioperative period. This thrombosis risk is possibly increased by the stress response to major surgery. The stress response includes sympathetic activation promoting shear stress on arterial plaques, enhanced vascular reactivity conducive to vasospasm, reduced fibrinolytic activity, platelet activation, and hypercoagulability. Because procoagulant clotting factors increase while fibrinolysis decreases, the surgical patient is in a hypercoaguable state. Furthermore, coronary stenting results in denudation of the endothelial surface. This might also contribute to the high risk of patients with early surgery because re-endothelization takes up to 8 weeks. This hypothesis is supported by our finding that
all MACEs in the early-surgery group occurred in patients in whom antiplatelet therapy was discontinued, including 3 events in the 17 patients with bare-metal stents in whom antiplatelet therapy was discontinued and 2 events in 9 patients with drug-eluting stents without antiplatelet therapy. In contrast to our findings, Reddy et al. (5) did not show an association between discontinuation of antiplatelet therapy and perioperative MACEs in 56 patients with prior bare-metal stenting. This might have been attributable to the small number of events in their study."
http://circ.ahajournals.org/cgi/content/full/116/16/e378
"When possible, surgery should be delayed until the patient is outside the recommended period of dual antiplatelet therapy, as determined by the stent and lesion characteristics. This would mean that surgery should be delayed until 6 weeks after implantation of a bare-metal stent and 1 year after implantation of a DES.
In reality, the recommendation for a 6-week delay with a bare-metal stent is to ensure that the patient completes a 4-week course of dual antiplatelet therapy because the patient will need 5 to 10 days (depending on the platelet half-life) for the effect of the antiplatelet agents to wear off before surgery.
21 Patients in whom noncardiac surgery is carried out within these time periods are deemed at high risk of stent thrombosis. Patients in whom noncardiac surgery is performed outside these time periods may still be at high risk of stent thrombosis, depending on factors related to their coronary anatomy and their clinical characteristics. Stent thrombosis is more likely to occur in patients who have had stenting of ostial lesions, bifurcation lesions, lesions in small vessels, multiple lesions, or long lesions. In addition, patients with diabetes mellitus or renal impairment or patients in whom the indication for stenting was an acute myocardial infarction or an acute coronary syndrome are at higher risk of stent thrombosis."
Found a little gem(2007):
we have adapted a table from Albaladejo et al
20 (2006)and incorporated the latest recommendations
http://circ.ahajournals.org/cgi/content-nw/full/116/16/e378/TBL2186852
Says for low risk of bleeding surgery it is ok to go to OR if antiplatelets are continued.